885340-13-6

Basic information

• Product Name: 1H-Indole-7-carbonitrile, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]aMino]propyl]-
• Synonyms: 1H-Indole-7-carbonitrile, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]aMino]propyl]-;2,3-Dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile;2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]aMino]propyl]-
• CAS NO: 885340-13-6
• Molecular Formula: C₂₅H₃₀F₃N₃O₃
• Molecular Weight: 477.5192096
• EINECS: -0
• Mol File: 885340-13-6.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 616.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.27±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: 14.84±0.10(Predicted)
• CAS DataBase Reference: 1H-Indole-7-carbonitrile, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]aMino]propyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-7-carbonitrile, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]aMino]propyl]-(885340-13-6)
• EPA Substance Registry System: 1H-Indole-7-carbonitrile, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]aMino]propyl]-(885340-13-6)

Safety Data

• Hazardous Substances Data: 885340-13-6(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 885340-13-6 differently. You can refer to the following data:
1. As an impurity in the synthesis of Silodosin (S465000),2,3-Dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]aMino]propyl]-1H-indole-7-carbonitrile is used in treatment of benign prostatic hypertophy.
2. An impurity in the synthesis of Silodosin (S465000), an α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertophy.

Upstream product

• 885340-12-5 (2R)-3-(7-cyano-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)-2,3-dihydro-1H-indol-1-yl)propyl benzoate oxalate 
• 90-05-1 2-methoxy-phenol 
• 120-80-9 benzene-1,2-diol 
• 885340-11-4 2,3-dihydro-1-[3-(benzoyloxy)propyl]-5-[(2R)-2-[[2-[(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile 
• 106854-74-4 2-methoxy-1-(2,2,2-trifluoroethoxy)benzene 
• 160968-99-0 2-O-(2,2,2-trifluoroethyl)catechol 
• 160969-02-8 2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethanol 
• 1269801-74-2 2-[2-(2,2,2-trifluoroethoxy)phenoxy-ethyl]-[1,3]dioxalane 
• 1269801-73-1 [2-(2,2,2-trifluoroethoxy)phenoxy]acetaldehyde 
• 496-15-1 1-indoline 
• 239463-72-0 5-[(2R)-2-aminopropyl]-2,3-dihydro-1-[3-(benzoyloxy)propyl]-1H-indole-7-carbonitrile 
• 350797-53-4 1-(3-benzoyloxypropyl)-5-(2-nitro-1-propenyl)-2,3-dihydroindole 
• 350797-54-5 1-(3-benzoyloxypropyl)-5-(2-nitropropyl)-2,3-dihydroindole 
• 350797-55-6 1-(3-benzoyloxypropyl)-7-formyl-5-(2-nitropropyl)-2,3-dihydroindole 

Downstream Products

• 160970-54-7 silodosin 

Relevant articles and documents

Preparation method of silodosin intermediate

The invention relates to a preparation method of a silodosin intermediate. The preparation method is characterized in that: the intermediate is 1-(3- hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxyl] phenoxyl] ethylamino] propyl]-7-nitrile-1H-indoline. The preparation method is shown in the description. The raw materials used in the method are sold on the market, are cheap, and are low in cost. The yield in various step is relatively high, and the post-processing is simple. The preparation method does not use poisonous or hazardous agent, and is convenient for industrialization. The product quality is high, and the optical purity is high.

NOVEL SULFONAMIDE INTERMEDIATE AND METHOD FOR PRODUCING SILODOSIN BY USING THE SAME

PROBLEM TO BE SOLVED: To provide a method for producing silodosin by using a novel sulfonamide intermediate. SOLUTION: The method for producing silodosin or a pharmaceutically acceptable salt thereof includes reacting a compound of the formula as given below and a thiol group-containing Meisenheimer complex forming agent in the presence of an alkali metal carbonate or an alkali metal alkoxide. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

THE PROCESS OF PREPARING INDOLINE COMPOUNDS AND A NOVEL INDOLINE SALT

The present invention provides an industrial method for production of silodosin, which is useful for a therapeutic agent for dysuria associated with benign prostatic hyperplasia. The production of silodosin is characterized by mixing (R)-l-(3-hydroxypropyl)-5-(2-(2- (2-(2, 2, 2-trifluoroethoxy) phenoxy) ethyl amino) propyl) indoline-7-carbonitrile (V) and N-acetyl-L-glutamic acid to yield the N-acetyl-L-glutamate salt, subsequently neutralising the N-acetyl-L-glutamate salt and hydrolyzing the same, and manufacturing intermediates used therefore. The invention also provides an industrial production method of silodosin alpha, beta and gamma crystalline forms.